Jackson Square Partners LLC Acquires 80,873 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Jackson Square Partners LLC increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 30.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 349,491 shares of the medical research company's stock after acquiring an additional 80,873 shares during the period. Charles River Laboratories International comprises approximately 2.7% of Jackson Square Partners LLC's holdings, making the stock its 17th largest holding. Jackson Square Partners LLC owned approximately 0.68% of Charles River Laboratories International worth $82,620,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Cardinal Capital Management lifted its holdings in Charles River Laboratories International by 0.6% during the 4th quarter. Cardinal Capital Management now owns 8,450 shares of the medical research company's stock worth $1,998,000 after buying an additional 47 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its stake in shares of Charles River Laboratories International by 21.5% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 328 shares of the medical research company's stock valued at $78,000 after purchasing an additional 58 shares during the period. Patriot Financial Group Insurance Agency LLC lifted its stake in shares of Charles River Laboratories International by 5.7% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 1,126 shares of the medical research company's stock valued at $266,000 after purchasing an additional 61 shares during the period. VisionPoint Advisory Group LLC lifted its stake in shares of Charles River Laboratories International by 45.1% in the 4th quarter. VisionPoint Advisory Group LLC now owns 209 shares of the medical research company's stock valued at $49,000 after purchasing an additional 65 shares during the period. Finally, M&T Bank Corp lifted its stake in shares of Charles River Laboratories International by 3.3% in the 3rd quarter. M&T Bank Corp now owns 2,076 shares of the medical research company's stock valued at $407,000 after purchasing an additional 66 shares during the period. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Stock Down 1.4 %

CRL stock traded down $3.14 during trading hours on Friday, reaching $221.61. 927,644 shares of the stock were exchanged, compared to its average volume of 587,008. The firm's 50-day moving average is $246.35 and its 200-day moving average is $227.90. The company has a market cap of $11.42 billion, a price-to-earnings ratio of 26.07, a PEG ratio of 1.75 and a beta of 1.44. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.75 and a quick ratio of 1.37. Charles River Laboratories International, Inc. has a 12 month low of $161.65 and a 12 month high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.05 by $0.22. The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 11 earnings per share for the current year.

Analyst Ratings Changes

CRL has been the topic of a number of analyst reports. StockNews.com raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Friday. Citigroup raised their price objective on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a "neutral" rating in a research note on Thursday, February 15th. Argus raised their price objective on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a "buy" rating in a research note on Monday, March 18th. TD Cowen dropped their price objective on Charles River Laboratories International from $260.00 to $228.00 and set a "hold" rating on the stock in a research note on Monday, May 13th. Finally, TheStreet raised Charles River Laboratories International from a "c+" rating to a "b-" rating in a research note on Friday, March 1st. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $255.27.

Insider Activity

In other news, EVP Victoria L. Creamer sold 5,000 shares of the firm's stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the transaction, the executive vice president now owns 13,550 shares in the company, valued at approximately $3,437,635. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Joseph W. Laplume sold 1,304 shares of Charles River Laboratories International stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the transaction, the executive vice president now owns 23,276 shares in the company, valued at $5,282,953.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Victoria L. Creamer sold 5,000 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the transaction, the executive vice president now owns 13,550 shares of the company's stock, valued at approximately $3,437,635. The disclosure for this sale can be found here. Insiders sold 10,354 shares of company stock worth $2,570,894 in the last quarter. Corporate insiders own 1.30% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).